Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

We conducted a phase 1/2 study of bortezomib administered in combination with high-dose melphalan followed by tandem autologous transplants in patients with primary resistant multiple myeloma. Thirty patients received 2 cycles of salvage bortezomib followed by stem cell mobilization with G-CSF and h...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Nishihori, Taiga, Alekshun, Todd J., Shain, Kenneth, Sullivan, Daniel M., Baz, Rachid, Perez, Lia, Pidala, Joseph, Kharfan-Dabaja, Mohamed A., Ochoa-Bayona, Jose L, Fernandez, Hugo F, Yarde, Danielle N., Oliveira, Vasco, Fulp, William, Han, Gang, Kim, Jongphil, Chen, Dung-Tsa, Raychaudhuri, Jyoti, Dalton, William, Anasetti, Claudio, Alsina, Melissa
פורמט: Artigo
שפה:Inglês
יצא לאור: 2012
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4030553/
https://ncbi.nlm.nih.gov/pubmed/22449149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2012.09099.x
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים